ReviewInternational urology and nephrology2026
Knowledge domains and emerging trends in aldosterone and kidney disease prognosis: a bibliometric analysis.
Review in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Precision nanomedicine in kidney disease: targeting inflammation and repair for clinical translation.International urology and nephrology · 2026Article
- Clinical translation of renal nanotherapeutics: addressing key unmet challenges.International urology and nephrology · 2026Article
- Critical appraisal of "Precision nanotherapeutics for kidney disease: targeting inflammation and maladaptive repair".International urology and nephrology · 2026Article
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
Abstract
purposeAldosterone plays a key role in kidney disease, but previous bibliometric studies have focused only broadly on the renin-angiotensin-aldosterone system (RAAS) or chronic kidney disease (CKD) as a whole. A focused bibliometric analysis specifically on aldosterone and kidney disease prognosis has been lacking. This study addresses that gap by mapping global research trends, identifying leading contributors, and pinpointing current priorities in this field.
methodsWe searched the Web of Science Core Collection for studies published between January 1, 1963, and May 6, 2025. Using VOSviewer, CiteSpace, and the R package "bibliometrix," we analyzed collaboration networks, author and institutional productivity, journal impact, keyword co-occurrence, and research trends.
resultsA total of 1338 articles from 5628 institutions in 77 countries were included. The United States led in publication output and collaboration, with China and Japan following. Harvard University, INSERM, and Harvard Medical Affiliates were the most productive institutions. The most influential authors were Pitt Bertram, Zannad Faiez, and Rossignol Patrick. Top journals included Kidney International and the American Journal of Kidney Diseases. Common keywords were "mortality," "risk," "blood pressure," "aldosterone," and "chronic kidney disease." Recent research has focused on "management," "serum potassium," "mineralocorticoid receptor antagonists," and "meta-analysis," reflecting shifts toward optimizing therapy and improving safety.
conclusionThis targeted bibliometric analysis fills a specific gap by clarifying how aldosterone research shapes our understanding of kidney disease prognosis. The findings highlight the need for more integrated, multidisciplinary approaches and support continued clinical and translational research to refine therapies and improve patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.